Literature DB >> 14722303

Systemic immune deficiency necessary for cytomegalovirus invasion of the mature brain.

Jon D Reuter1, Daniel L Gomez, Jean H Wilson, Anthony N Van Den Pol.   

Abstract

Cytomegalovirus (CMV) is a significant opportunistic pathogen associated with AIDS and immunosuppressive therapy. Infection of the mature central nervous system (CNS) can cause significant pathology with associated neurological deficits, mental disorders, and cognitive impairment and may have potentially fatal consequences. Using genetically immunocompromised mice, we studied mechanisms of CMV invasion into, and behavior within, the CNS. Adult immunodeficient (nude and SCID) and control mice were peripherally infected with recombinant mouse CMV expressing a green fluorescent protein reporter gene. Control mice actively eliminated acute peripheral infection and were resistant to invasion of CMV into the brain. In contrast, virus infected brains of immunodeficient mice but only after a minimum of 21 days postinoculation. After inoculation, CMV was found in circulating leukocytes (MAC-3/CD45(+)) and in leukocytes within the brain, suggesting these cells as a possible source of CMV entry into the CNS. CNS infection was observed in many different cell types, including neurons, glial cells, meninges, ependymal cells, and cells of cerebral vessels. Infection foci progressively expanded locally to adjacent cells, resulting in meningitis, choroiditis, encephalitis, vasculitis, and necrosis; clear indication of axonal transport of CMV was not found. Regional distribution of CMV was unique in each brain, consisting of randomly distributed, unilateral foci. Testing whether CMV gained access to brain through nonspecific vascular disruption, vascular injections of a tracer molecule revealed no obvious disruption of the blood brain barrier in mice with CMV in the brain. Results indicate the importance of host adaptive immunity (particularly T cells) in controlling entry and dissemination of CMV into the brain and are consistent with the view that virus may be carried into the brain by circulating mononuclear cells that traffic through the blood brain barrier.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722303      PMCID: PMC321365          DOI: 10.1128/jvi.78.3.1473-1487.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance.

Authors:  S K Seo; A Regan; T Cihlar; D C Lin; F Boulad; D George; V K Prasad; T E Kiehn; B Polsky
Journal:  Clin Infect Dis       Date:  2001-09-26       Impact factor: 9.079

2.  Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.

Authors:  N Kröger; T Zabelina; W Krüger; H Renges; N Stute; J Schrum; H Kabisch; P Schafhausen; N Jaburg; C Löliger; P Schäfer; A Hinke; A R Zander
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

3.  Effect of immunization of mothers on cytomegalovirus infection in suckling mice.

Authors:  D N Medearis; S L Prokay
Journal:  Proc Soc Exp Biol Med       Date:  1978-04

4.  Immune responses and cytokine induction in the development of severe hepatitis during acute infections with murine cytomegalovirus.

Authors:  J Trgovcich; D Stimac; B Polić; A Krmpotić; E Pernjak-Pugel; J Tomac; M Hasan; B Wraber; S Jonjić
Journal:  Arch Virol       Date:  2000       Impact factor: 2.574

5.  Entry of peroxidase into neurons of the central and peripheral nervous systems from extracerebral and cerebral blood.

Authors:  R D Broadwell; M W Brightman
Journal:  J Comp Neurol       Date:  1976-04-01       Impact factor: 3.215

6.  Mouse cytomegalovirus in developing brain tissue: analysis of 11 species with GFP-expressing recombinant virus.

Authors:  A N Van Den Pol; J Vieira; D D Spencer; J G Santarelli
Journal:  J Comp Neurol       Date:  2000-11-27       Impact factor: 3.215

7.  Risk factors for chronic rejection after pediatric liver transplantation.

Authors:  P Gupta; J Hart; D Cronin; S Kelly; J M Millis; L Brady
Journal:  Transplantation       Date:  2001-09-27       Impact factor: 4.939

8.  Enhanced cytomegalovirus infection of developing brain independent of the adaptive immune system.

Authors:  Anthony N van den Pol; Jon D Reuter; Justin G Santarelli
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Role of T lymphocytes in recovery from murine cytomegalovirus infection.

Authors:  S E Starr; A C Allison
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

10.  A recombinant rhesus cytomegalovirus expressing enhanced green fluorescent protein retains the wild-type phenotype and pathogenicity in fetal macaques.

Authors:  W L William Chang; Alice F Tarantal; Shan Shan Zhou; Alexander D Borowsky; Peter A Barry
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more
  25 in total

1.  Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities.

Authors:  Sara Ornaghi; Lawrence S Hsieh; Angélique Bordey; Patrizia Vergani; Michael J Paidas; Anthony N van den Pol
Journal:  J Neurosci       Date:  2017-06-19       Impact factor: 6.167

Review 2.  Cytomegalovirus and schizophrenia.

Authors:  E Fuller Torrey; Markus F Leweke; Markus J Schwarz; Norbert Mueller; Silke Bachmann; Johannes Schroeder; Faith Dickerson; Robert H Yolken
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  CD4+ T-cell reconstitution reduces cytomegalovirus in the immunocompromised brain.

Authors:  Jon D Reuter; Jean H Wilson; Kimberly E Idoko; Anthony N van den Pol
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Herpesvirus infections of the central nervous system in immunocompromised patients.

Authors:  Uta Meyding-Lamadé; Cornelia Strank
Journal:  Ther Adv Neurol Disord       Date:  2012-09       Impact factor: 6.570

5.  Transmission of murine cytomegalovirus in breast milk: a model of natural infection in neonates.

Authors:  Carol A Wu; Sara A Paveglio; Elizabeth G Lingenheld; Li Zhu; Leo Lefrançois; Lynn Puddington
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

Review 6.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

7.  Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.

Authors:  Steven R Wilson; Jean H Wilson; Linda Buonocore; Amy Palin; John K Rose; Jon D Reuter
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

Review 8.  Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention.

Authors:  Maxim C-J Cheeran; James R Lokensgard; Mark R Schleiss
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

9.  Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice.

Authors:  Durdica Cekinović; Mijo Golemac; Ester Pernjak Pugel; Jelena Tomac; Luka Cicin-Sain; Irena Slavuljica; Russell Bradford; Sonja Misch; Thomas H Winkler; Michael Mach; William J Britt; Stipan Jonjić
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

10.  Cytomegalovirus infection and interferon-gamma modulate major histocompatibility complex class I expression on neural stem cells.

Authors:  Maxim C-J Cheeran; Zibing Jiang; Shuxian Hu; Hsiao T Ni; Joseph M Palmquist; James R Lokensgard
Journal:  J Neurovirol       Date:  2008-10-18       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.